Drug Trial Radar · NCT03409614
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
789
Actual
Start
Mar 6, 2018
Primary completion
Feb 27, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Jan 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression. The key secondary objectives are: Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.
Conditions
- Non-small Cell Lung Cancer
Interventions
REGN2810Drug
REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
REGN2810/chemo/ipiDrug
REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
ChemotherapyOther
Platinum-based doublet chemotherapy Part 1
PlaceboDrug
Matching placebo Part 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Overall Survival (OS)Time frame: Up to a maximum of 82.2 months
- Part 2: OSTime frame: Up to a maximum of 68.4 months
Locations
133 sites in 18 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Rancho Mirage, California
Regeneron Research Site
Riverside, California
Regeneron Research Site
Whittier, California
Regeneron Research Site
Orange City, Florida
Regeneron Research Site
St. Petersburg, Florida
Regeneron Research Site
Wichita, Kansas
Regeneron Research Site
Bethesda, Maryland
Regeneron Research Site
Farmington, New Mexico
Regeneron Research Site
Gettysburg, Pennsylvania
Regeneron Research Site
Vienna, Austria
Regeneron Research Site
Baoding, China
Regeneron research Site
Beijing, China
Regeneron Research Site
Changsha, China
Regeneron Research Site
Guangzhou, China
Regeneron Research Site
Hangzhou, China
Regeneron Research Site
Hangzhou, China
Regeneron Research Site
Hangzhou, China
Regeneron Research Site
Hangzhou, China
Regeneron Research Site
Jinan, China
Regeneron Research Site
Linyi, China
Regeneron Research Site
Nanjing, China
Regeneron Research Site
Shanghai, China
Regeneron Research Site
Shanghai, China
Regeneron Research Site
Shenyang, China
Regeneron Research Site
Xiangyang, China
Regeneron Research Site
Zhengzhou, China
Regeneron Research Site
Zhengzhou, China
Regeneron Research Site
Bayonne, France
Regeneron Research Site
Créteil, France
Regeneron Research Site
Le Mans, France
Regeneron Research Site
Lille, France
Regeneron Research Site
Lyon, France
Regeneron Research Site
Mont-de-Marsan, France
Regeneron Research Site
Saint-Herblain, France
Regeneron Research Site
Saint-Mandé, France
Regeneron Research Site
Strasbourg, France
Regeneron Research Site
Batumi, Georgia
Regeneron Research Site
Tbilisi, Georgia
Regeneron Research Site
Tbilisi, Georgia
Regeneron Research Site #1
Tbilisi, Georgia
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.